{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:43:03Z","timestamp":1792896183326,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.breast.2025.104565","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:53:32Z","timestamp":1756277612000},"page":"104565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Denosumab versus zoledronic acid in metastatic breast cancer: A retrospective observational analysis of 24-dose regimens on analgesia and skeletal-related event prevention"],"prefix":"10.1016","volume":"83","author":[{"given":"Giacomo","family":"Massa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Tin\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lo Dico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ricchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Valeria","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Caraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-0370","authenticated-orcid":false,"given":"Ernesto","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.breast.2025.104565_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.breast.2025.104565_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007702","article-title":"Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval","volume":"5","author":"Cetin","year":"2015","journal-title":"BMJ Open"},{"issue":"8 Suppl","key":"10.1016\/j.breast.2025.104565_bib3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2025.104565_bib4","author":"Coleman"},{"issue":"16","key":"10.1016\/j.breast.2025.104565_bib5","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1158\/1078-0432.CCR-10-0600","article-title":"Novel bone-targeted strategies in oncology","volume":"16","author":"Vallet","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2025.104565_bib6","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.breast.2025.104565_bib7","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.breast.2025.104565_bib8","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.breast.2025.104565_bib9","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.breast.2025.104565_bib10","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2025.104565_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.breast.2025.104565_bib12","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.breast.2025.104565_bib13","first-page":"1029","article-title":"Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Menshawy","year":"2018","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.breast.2025.104565_bib14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.21.02647","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update","volume":"40","author":"Eisen","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104565_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h315","article-title":"Cancer induced bone pain","volume":"350","author":"Kane","year":"2015","journal-title":"Br Med J"},{"issue":"12","key":"10.1016\/j.breast.2025.104565_bib16","first-page":"3497","article-title":"Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid","volume":"21","author":"von Moos","year":"2013","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.breast.2025.104565_bib17","first-page":"1157","article-title":"Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents","volume":"23","author":"Patrick","year":"2015","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.breast.2025.104565_bib18","first-page":"CD002068","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","volume":"2002","author":"Wong","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.breast.2025.104565_bib19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.breast.2025.104565_bib20","first-page":"1327","article-title":"Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases","volume":"24","author":"von Moos","year":"2016","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.breast.2025.104565_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0269216316639793","article-title":"Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project","volume":"31","author":"Porta-Sales","year":"2017","journal-title":"Palliat Med"},{"issue":"4","key":"10.1016\/j.breast.2025.104565_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"STROBE initiative. The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.breast.2025.104565_bib23","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/pm\/pnab110","article-title":"Associations of pain numeric rating scale scores collected during usual care with research administered patient reported pain outcomes","volume":"22","author":"Nugent","year":"2021","journal-title":"Pain Med"},{"issue":"4","key":"10.1016\/j.breast.2025.104565_bib24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1","article-title":"A validation study of the WHO method for cancer pain relief","volume":"59","author":"Ventafridda","year":"1987","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.breast.2025.104565_bib25","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104565_bib26","series-title":"Common terminology criteria for adverse events (CTCAE)","year":"2017"},{"issue":"3","key":"10.1016\/j.breast.2025.104565_bib28","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Stat"},{"issue":"17","key":"10.1016\/j.breast.2025.104565_bib29","doi-asserted-by":"crossref","first-page":"18317","DOI":"10.1002\/cam4.6429","article-title":"A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab","volume":"12","author":"Bracchi","year":"2023","journal-title":"Cancer Med"},{"issue":"1\u20132","key":"10.1016\/j.breast.2025.104565_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.breast.2025.104565_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00774-020-01178-y","article-title":"Regulation of T cell-associated tissues and T cell activation by RANKL-RANK-OPG","volume":"39","author":"Walsh","year":"2021","journal-title":"J Bone Miner Metabol"},{"issue":"1","key":"10.1016\/j.breast.2025.104565_bib32","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1038\/s41467-020-20138-8","article-title":"Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells","volume":"11","author":"G\u00f3mez-Aleza","year":"2020","journal-title":"Nat Commun"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762500582X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762500582X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:09:55Z","timestamp":1762344595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762500582X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"alternative-id":["S096097762500582X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104565","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab versus zoledronic acid in metastatic breast cancer: A retrospective observational analysis of 24-dose regimens on analgesia and skeletal-related event prevention","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104565"}}